Peptides for SIBO and Hashimoto's: what the evidence actually shows

What did @lizigrace_ actually say?

Honestly, there is not much to work with here. The captured transcript is just "Just trust me you'll be fine. And when I'm back in Chicago I feel it." That is almost nothing. The caption fills in more context: she describes daily bloating so severe it made her cry, a frustrating experience with one doctor, and eight months of work with a second provider. The hashtags point toward SIBO, Hashimoto's, leaky gut, and gut healing, and the video is categorized under peptide therapy. So the implied claim is that peptide-based treatment, pursued through telehealth care, resolved symptoms that conventional medicine missed. She does not state a specific peptide by name in the transcript, but the category context matters here.

The phrase "just trust me you'll be fine" is doing a lot of heavy lifting for a 1.2 million-view video about a medical journey. Trust is not a mechanism of action. That framing deserves scrutiny before anything else.

Does the science back this up?

It depends entirely on which peptide was used and for what. The category covers a wide range, from BPC-157 to ipamorelin to GHK-Cu, and they do not all have equivalent evidence. BPC-157 has shown gut-protective effects in rodent models, including accelerating healing of intestinal anastomoses and reducing colitis markers, but human clinical trials are sparse. Sikiric et al. (2018, Current Pharmaceutical Design) documented its gastrointestinal effects in animal models, but that is not the same as proof it resolves SIBO or Hashimoto's in humans.

Hashimoto's is an autoimmune thyroid condition. There is no published human trial demonstrating that any peptide in this category treats or reverses Hashimoto's disease. SIBO has established antibiotic protocols, rifaximin being the most studied (Pimentel et al., 2011, Annals of Internal Medicine). Peptide therapy is not part of any current SIBO treatment guideline. The bloating-to-resolution arc she describes is plausible with proper SIBO treatment, but attributing that to peptides without specifics is a stretch.

What did they get wrong (or right)?

She probably got something right: finding a provider who actually listens changes outcomes. Research on the therapeutic relationship consistently shows that concordance between patient and provider improves adherence and symptom reporting accuracy (Kelley et al., 2014, PLOS ONE). Eight months of consistent care with one doctor, rather than bouncing between providers, is genuinely useful. Credit where it is due.

What is harder to accept is the implied causality. "Just trust me you'll be fine" assigns the outcome to the treatment category without naming the treatment, the dose, or the diagnostic workup. That is not how any of this works. Symptoms like bloating, fatigue, and mood disruption have dozens of explanations. If SIBO was confirmed by breath testing and treated with an appropriate protocol, the improvement makes clinical sense. If peptides were added on top of that, we cannot know which intervention drove the result. Post hoc reasoning dressed up as a healing journey is one of the more persistent problems in wellness content.

What should you actually know?

Peptides like BPC-157 are not FDA-approved treatments for SIBO, Hashimoto's, leaky gut, or any other condition she mentioned. Most are compounded, which means quality, purity, and dosing consistency vary considerably across pharmacies. The FDA placed BPC-157 on its list of substances that cannot be compounded under section 503A in 2022, though enforcement has been inconsistent. Ipamorelin and CJC-1295 are growth hormone secretagogues with cardiovascular and metabolic considerations that require real clinical oversight, not a TikTok recommendation.

Hashimoto's management typically requires thyroid hormone replacement, lifestyle modification, and sometimes selenium supplementation based on actual evidence (Toulis et al., 2010, Thyroid). SIBO needs a confirmed diagnosis and targeted treatment. If someone is relating to this video because they have similar symptoms, the move is a workup with a gastroenterologist, not a peptide protocol built on a social media hashtag.

Getting care from a provider who takes your symptoms seriously matters. The platform, the peptides, and the vague testimonial framing matter a lot less than that.